EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers

NANot yet recruitingINTERVENTIONAL
Enrollment

1,161

Participants

Timeline

Start Date

September 1, 2026

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Low-Value Care
Interventions
OTHER

EVOLV-Rx dashboard

Using the TheraDoc® platform, the investigators will deploy a custom-designed EVOLV-Rx dashboard that incorporates all 18 components of the EVOLV-Rx metric. \[Within TheraDoc®, the dashboard will display an automated report in the form of a patient list that includes the names, locations, and specific LVP practices to which Veterans under their care are subject. Pharmacists will then query specific patients on the list as part of their required medication review. The dashboard will provide detailed clinical decision support by identifying the specific EVOLV-Rx LVP criteria met by each flagged medication and provide access to the patient's full medication list, problem list, and laboratory or testing data contained within VISTA.\] Pharmacists may use the EVOLV-Rx dashboard to track Veterans' receipt of LVP practices and quickly document actions related to the intervention, such as patient and family caregiver engagement, deprescribing LVP practices, or any other medications discontinued.

Trial Locations (2)

15240

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh

19104-4551

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT07166107 - EVOLV-Rx VA: Evaluating Opportunities to Decrease Low-Value Prescribing in Community Living Centers | Biotech Hunter | Biotech Hunter